Mustang Bio, Inc. (ticker: MBIO) is a clinical-stage biopharmaceutical company based in Worcester, Massachusetts, committed to advancing innovative cell and gene therapies aimed at addressing hematologic cancers, solid tumors, and rare genetic disorders. With a robust pipeline leveraging cutting-edge technologies, Mustang Bio is dedicated to transforming patient outcomes through its focus on developing potentially curative treatments. The company's expertise in gene editing and its collaborative approach to research underscore its potential to lead in the rapidly evolving biotherapeutics landscape.